In this regard, a therapeutic with BIM SAHBA’s therapeutic profile could be of particular benefit against activated B-cell like (ABC) DLBCLs that express MCL1 at higher levels and have higher MCL-1:BIM binding than germinal center B-cell like (GCB) DLBCL [12]. The gene discussed is MCL1; the disease is diffuse large B-cell lymphoma.